DNA methylation markers for early detection of women's cancer: Promise and challenges

Epigenomics

Volumn 6, Issue 3, 2014, Pages 311-327

  Wittenberger, Timo ^a   Sleigh, Sara ^b   Reisel, Daniel ^c   Zikan, Michal ^d   Wahl, Benjamin ^e   Alunni Fabbroni, Marianna ^f   Jones, Allison ^c   Evans, Iona ^c   Koch, Julian ^f   Paprotka, Tobias ^e   Lempiäinen, Harri ^a   Rujan, Tamas ^a   Rack, Brigitte ^f   Cibula, David ^d   Widschwendter, Martin ^c  

^a GENEDATA AG   (Switzerland)

^b Euram Ltd   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHARLES UNIVERSITY   (Czech Republic)

^e GATC Biotech AG   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

cancer; circulating cell free DNA; digital PCR; DNA methylation; epigenetics; methylation arrays; personalized medicine; plasma; reduced representation bisulfite sequencing; screening; serum

Indexed keywords

TUMOR MARKER;

BREAST NEOPLASMS; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENETICS; GENITAL NEOPLASMS, FEMALE; GENOMICS; HUMAN; PERSONALIZED MEDICINE; PROCEDURES;

BREAST NEOPLASMS; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GENITAL NEOPLASMS, FEMALE; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905814375     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.20     Document Type: Review

References (72)

1. American Cancer Society, GA, USA: Cancer Facts and Figures 2013. www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/document/ acspc-036845.pdf
2. European Commission's Eurostat, Luxembourg: Health Statistics. http://epp.eurostat.ec.europa.eu/
3. Weaver DL, Ashikaga T, Krag DN et al. Effect of occult metastases on survival in node-negative breast cancer. N. Engl. J. Med. 364(5), 412-421 (2011
4. Rosner D, Lane WW. Predicting recurrence in axillarynode negative breast cancer patients. Breast Cancer Res. Treat. 25(2), 127-139 (1993
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009
6. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol. 33(2 Suppl. 6), S3-S11 (2006
7. Sorosky JI. Endometrial cancer. Obstet. Gynecol. 111(2 Pt 1), 436-447 (2008
8. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol. Oncol. 101(1), 158-167 (2006
9. Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr. Relat. Cancer 16(2), 363-380 (2009
10. Arbyn M, Anttila A, Jordan J et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann. Oncol. 21, 448-458 (2010
11. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22), 2295-2303 (2011
12. Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10(4), 327-340 (2009
13. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 4(1), 1-12 (1989
14. Moore RG, McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 112(1), 40-46 (2009
15. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 97(10), 922-929 (1990
16. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet. Gynecol. 113(2 Pt 1), 384-394 (2009
17. Yazbek J, Raju SK, Ben-Nagi J, Holland TK, Hillaby K, Jurkovic D. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. Lancet Oncol. 9(2), 124-131 (2008
18. Welch HG, Frankel BA. Likelihood that a woman with screen-detected breast cancer has had her 'life saved' by that screening. Arch. Intern. Med. 171, 2043-2046 (2011
19. Mook S, Van't Veer LJ, Rutgers EJ et al. Independent prognostic value of screen detection in invasive breast cancer. J. Natl Cancer Inst. 103, 585-597 (2011
20. Zahl PH, Gotzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol. 12, 1118-1124 (2011
21. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339, b2587 (2009
22. Warner E. Clinical practice. Breast-cancer screening. N. Engl. J. Med. 365, 1025-1032 (2011
23. Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J. Natl Cancer Inst. 101, 1216-1220 (2009
24. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013
25. Pessoa JN, Freitas AC, Guimaraes RA, Lima J, Dos Reis HL, Filho AC. Endometrial assessment: when is it necessary? J. Clin. Med. Res. 6(1), 21-25 (2014
26. Tavasolli FA, Devilee P. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, France (2004
27. Langer RD, Pierce JJ, O'Hanlan KA et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. N. Engl. J. Med. 337(25), 1792-1798 (1997
28. Fleischer AC, Wheeler JE, Lindsay I et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am. J. Obstet. Gynecol. 184(2), 70-75 (2001
29. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11(6), 541-552 (2006
30. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054-1061 (2001
31. Teschendorff AE, Menon U, Gentry-Maharaj A et al. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE 4, e8274 (2009
32. Andriole GL, Crawford ED, Grubb RL et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009
33. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295-2303 (2011
34. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328 (2009
35. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128, 683-692 (2007
36. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17, 330-339 (2011
37. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39(2), 157-158 (2007
38. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat. Res. 635, 105-117 (2007
39. Weisenberger DJ, Trinh BN, Campan M et al. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res. 36, 4689-4698 (2008
40. Weber M, Davies JJ, Wittig D et al. 2005. Chromosomewide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37, 853-862 (2005
41. Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG. Whole-genome DNA methylation profiling using MethylCap-seq. Methods 52, 232-236 (2010
42. Rauch T, Pfeifer GP. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab. Invest. 85(9), 1172-1180 (2005
43. Serre D, Lee BH, Ting AH. MBD-isolated genome sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res. 38(2), 391-399 (2010
44. Bock CE, Tomazou EM, Brinkman AB et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotechnol. 28(10), 1106-1114 (2010
45. Bock C. Analysing and interpreting DNA methylation data. Nat. Rev. Genet. 13(10), 705-719 (2012
46. The Cancer Genome Atlas. http://cancergenome.nih.gov/
47. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22, 2990-2997 (1994
48. Frommer M, McDonald LE, Millar DS et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89, 1827-1831 (1992
49. Harris RA, Wang T, Coarfa C et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat. Biotechnol. 28(10), 1097-1105 (2010
50. Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat. Protoc. 6, 468-481 (2011
51. Chatterjee A, Rodger EJ, Stockwell PA, Weeks RJ, Morison IM. Technical considerations for reduced representation bisulfite sequencing with multiplexed libraries. J. Biomed. Biotechnol. 1-8 (2012) (2012
52. Gu H, Bock C, Mikkelsen TS. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution. Nat. Methods 7, 133-136 (2010
53. Ellinger J, El Kassem N, Heukamp LC et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179, 346-352 (2008
54. Quail MA, Smith M, Coupland P et al. A tale of three next generation sequencing platforms: comparison of Ion torrent, pacific biosciences and illumina MiSeq sequencers. BMC Genomics 13, 341 (2012
55. Mardis ER. A decade's perspective on DNA sequencing technology. Nature 470, 198-203 (2011
56. Illumina. www.illumina.com
57. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-6982 (1996
58. Eads CA, Danenberg KD, Kawakami K et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28, E32 (2000
59. Weisenberger DJ, Trinh BN, Campan M et al. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res. 36, 4689-4698 (2008
60. Zimmermann B, Grill S, Holzgreve W, Zhong XY, Jackson LG, Hahn S. Digital PCR: a powerful new tool for noninvasive prenatal diagnosis? Prenat. Diagn. 28, 1087-1093 (2008
61. Hindson CM, Chevillet JR, Briggs HA et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10, 1003-1005 (2013
62. Varley KE, Mitra RD. Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. Genome Res. 20, 1279-1287 (2010
63. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530-9535 (2011
64. Lee da E, Kim SY, Lim JH, Park SY, Ryu HM. Non-invasive prenatal testing of trisomy 18 by an epigenetic marker in first trimester maternal plasma. PLoS ONE 8(11), e78136 (2013
65. Cancer Genome Atlas Research Network, Weinstein JN, Collinson EA et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. Nat. Genet. 45(10), 1113-1120 (2013
66. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the infinium methylation 450K technology. Epigenomics 3(6), 771-784 (2011
67. Maksimovic J, Gordon L, Oshlack A. SWAN: Subsetquantile within array normalization for Illumina Infinium Human Methylation450 BeadChips. Genome Biol. 13(6), R44 (2012
68. Marabita F, Almgren M, Lindholm ME et al. An evaluation of analysis pipelines for DNA methylation profiling using the Illumina Human Methylation450 BeadChip platform. Epigenetics 8(3), 333-346 (2013
69. Teschendorff AE, Marabita F, Lechner M et al. A betamixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics 29(2), 189-196 (2013
70. Chatterjee A, Stockwell PA, Rodger EJ, Morison IM. Comparison of alignment software for genome-wide bisulphite sequence data. Nucleic Acids Res. 40(10), e79 (2012
71. Chen PY, Cokus SJ, Pellegrini M. BS Seeker: precise mapping for bisulfite sequencing. BMC Bioinformatics 11, 203 (2010
72. Jaffe AE, Murakami P, Lee H et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int. J. Epidemiol. 41(1), 200-209 (2012).